Leading cardiometabolic disease experts to support the continued clinical development of the Company’s diverse pipeline of ...

The quest for wellness is increasingly as much about the people you meet along the way as the physical health benefits. That ...

For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious ...

People with diabetes who were taking GLP-1 receptor agonist drugs such as tirzepatide and semaglutide had significantly lower ...

With its innovative features and the upcoming launch of a direct medication purchasing service, Gala is set to become the ...

Results showed patients with a BMI of 40 kg/m2 or more who used glucagon-like peptide-1 receptor agonists for at least 90 ...

Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...

Research showed that patients who lose weight on GLP-1 agonists frequently experience muscle mass loss. Obesity experts share ...

Metsera's MET-097i shows 11.3% weight loss in Phase 2a trial, beating Wegovy and Zepbound at 3 months, with potential for ...

What does the latest science say about the use of GLP-1 meds to treat obesity in people without diabetes?A review of 26 ...

Investigational once-weekly retatrutide yielded the greatest weight loss of all GLP-1 receptor agonists, up to 22.1% after 48 weeks in adults with overweight or obesity and without diabetes, according ...

Surgeons are collaborating with obesity medicine physicians, turning to GLP-1s to help high BMI patients qualify for surgery.